Your browser doesn't support javascript.
loading
Inhibition of de novo ceramide synthesis by Sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes.
Velagapudi, Srividya; Karsai, Gergely; Karsai, Maria; Mohammed, Shafeeq A; Montecucco, Fabrizio; Liberale, Luca; Lee, Hwan; Carbone, Federico; Francesco Adami, Giovanni; Yang, Kangmin; Crucet, Margot; Stein, Sokrates; Paneni, Franceso; Lapikova-Bryhinska, Tetiana; Jang, Hyun-Duk; Kraler, Simon; Vdovenko, Daria; Arnold Züllig, Richard; Camici, Giovanni G; Kim, Hyo-Soo; Laaksonen, Reijo; Gerber, Philipp A; Hornemann, Thorsten; Akhmedov, Alexander; Lüscher, Thomas F.
Afiliación
  • Velagapudi S; Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
  • Karsai G; Institute of Clinical Chemistry, University Hospital Zürich, Zürich, Switzerland.
  • Karsai M; Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
  • Mohammed SA; Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, Zurich University Hospital and University of Zürich, Zürich, Switzerland.
  • Montecucco F; First Clinic of Internal Medicine, University of Genoa School of Medicine, Genoa, Italy.
  • Liberale L; IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, Genoa, Italy.
  • Lee H; First Clinic of Internal Medicine, University of Genoa School of Medicine, Genoa, Italy.
  • Carbone F; IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, Genoa, Italy.
  • Francesco Adami G; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Yang K; First Clinic of Internal Medicine, University of Genoa School of Medicine, Genoa, Italy.
  • Crucet M; IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, Genoa, Italy.
  • Stein S; First Clinic of Internal Medicine, University of Genoa School of Medicine, Genoa, Italy.
  • Paneni F; Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
  • Lapikova-Bryhinska T; Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
  • Jang HD; Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
  • Kraler S; Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, Zurich University Hospital and University of Zürich, Zürich, Switzerland.
  • Vdovenko D; Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
  • Arnold Züllig R; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Camici GG; Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
  • Kim HS; Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
  • Laaksonen R; Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
  • Gerber PA; Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
  • Hornemann T; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Akhmedov A; Zora Biosciences and Finnish Cardiovascular Research Center, Tampere University, Tampere, Finland.
  • Lüscher TF; Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
Cardiovasc Res ; 2024 May 13.
Article en En | MEDLINE | ID: mdl-38739545
ABSTRACT

BACKGROUND:

Obesity and type 2 diabetes (T2D) are major risk factors for cardiovascular diseases (CVD). Dysregulated pro-apoptotic ceramide synthesis reduces ß-cell insulin secretion, thereby promoting hyperglycemic states which may manifest as T2D. Pro-apoptotic ceramides modulate insulin sensitivity and glucose tolerance while being linked to poor cardiovascular outcomes. Sirtuin-1 (SIRT1) is a NAD + - dependent deacetylase that protects against pancreatic ß-cell dysfunction; however, systemic levels are decreased in obese T2D mice and may promote pro-apoptotic ceramide synthesis and hyperglycemia. Herein, we aimed to assess the effects of restoring circulating SIRT1 levels to prevent metabolic imbalance in obese and diabetic mice. METHODS AND

RESULTS:

Circulating SIRT1 levels were reduced in obese diabetic mice (db/db) as compared to age-matched non-diabetic db/+ controls. Restoration of SIRT1 plasma levels with recombinant murine SIRT1 for 4-weeks prevented body weight gain, improved glucose tolerance, insulin sensitivity and vascular function in mice models of obesity and T2D. Untargeted lipidomics revealed that SIRT1 restored insulin-secretory function of ß-cells by reducing synthesis and accumulation of pro-apoptotic ceramides. Molecular mechanisms involved direct binding to and deacetylation of Toll-like receptor 4 (TLR4) by SIRT1 in ß-cells thereby decreasing the rate limiting enzymes of sphingolipid synthesis SPTLC1/2 via AKT/NF-κB. Among T2D patients, those with high baseline plasma levels of SIRT1 prior to metabolic surgery displayed restored ß-cell function (HOMA2- ß) and were more likely to have T2D remission during follow-up.

CONCLUSION:

Acetylation of TLR4 promotes ß-cell dysfunction via ceramide synthesis in T2D, which is blunted by systemic SIRT1 replenishment. Hence, restoration of systemic SIRT1 may provide a novel therapeutic strategy to counteract toxic ceramide synthesis and mitigate cardiovascular complications of T2D.
Palabras clave

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Cardiovasc Res Año: 2024 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Cardiovasc Res Año: 2024 Tipo del documento: Article País de afiliación: Suiza